-
Voice of China What are the benefits of robotic surgery for patients with low- and middle-grade rectal cancer? Chinese data gives the answer!
Time of Update: 2022-10-13
Coloral cancer is one of the most common malignancies in the world, and surgical resection is an important radical means of curing colorectal cancer. With the advancement of surgical technology, minim
-
Express First-line treatment of lung cancer, LAG-3 therapy is FDA fast-track qualified
Time of Update: 2022-10-13
Image source: Immutep websiteThe results of the clinical trials presented at this year's ASCO Annual Meeting showed that in the Phase 2 clinical trial, efti was combined with Keytruda, and the first-line treatment of NSCLC patients reached an objective response rate (ORR) of 38.
-
Can EGFR gene mutations also be inherited? How are patients with this lung cancer treated?
Time of Update: 2022-10-13
Patients with germ cell EGFR gene mutations can benefit from PD-1 inhibitor therapy, let's take a look at the following cases.
Patients with germ cell EGFR gene mutations can benefit from PD-1 inhibitor therapy, let's take a look at the following cases.
-
Clinically necessary Expert consensus on the preservation of comprehensive bladder treatment for muscularly invasive bladder cancer
Time of Update: 2022-10-13
Table 1 The consensus of MIBC retains the content of comprehensive bladder treatmentEdit: LRReviewer: LRExecution: Wang MumuGuideRadical cystectomy (RC) is the main surgical modality for the treatment of muscularly invasive bladder cancer (MIBC) and is effective in improving patient survival.
-
Overview of CAR T cell therapy for the treatment of malignant brain tumors in children
Time of Update: 2022-10-13
】 Research background Childhood central nervous system (CNS) tumors are solid malignancies, including medulloblastoma (MB), high-grade glioma in children, and ependymoma.
】 Research background Childhood central nervous system (CNS) tumors are solid malignancies, including medulloblastoma (MB), high-grade glioma in children, and ependymoma.
-
Synthetic RNA viruses are injected to treat cancer and address the limitations of oncolytic viruses
Time of Update: 2022-10-13
Written by Wang Cong Editor Wang Duoyu typesetting Water Chengwen Oncolytic viruses (OV) has become a very attractive cancer treatment method, oncolytic virus targets cancer cells, without affecting n
-
Patients with brain metastases with lung cancer have been controlled by a ketogenic diet for up to 14 years
Time of Update: 2022-10-13
For example, in the newly published article below, a patient with brain metastases with lung cancer who uses a ketogenic diet to control the condition after chemoradiation and chemoradiation has benefited for up to 14 years without any treatment measures.
-
Nature Blockbuster: Refresh the perception that p53 mutations drive cancer! MSKCC scientists have found that p53 deletions induce predictable, orderly, and definite scientific discoveries in the evolution of the cancer genome
Time of Update: 2022-10-13
Based on the above results, it is not difficult to find that Lowe's team has gradually uncovered the evolutionary pattern of genomic certainty of PDAC: First, the cells appear p53 LOH; Subsequently, gene deletions accumulate and polyploids form; Finally, chromosome gain amplification yields more copy number changes.
-
【Cell】Latest research on cancer immunotherapy: Ye Lilin/Tang Zhonghui/Professor Sun Beicheng and others have discovered new tumor memory T cells
Time of Update: 2022-10-13
This article is the original of the translational medicine network, please indicate the source when reprinting Author: JevinRecent studies have shown that systemic tumor-responsive CD8 T cells may res
-
AM(IF=32) Tian Huayu's team at the Chinese Academy of Sciences has developed biomineralized dual-enzyme nanoparticles to achieve apoptosis of tumor cells and anti-tumor immunotherapy through glucose metabolism
Time of Update: 2022-10-13
This is the first research to combine tumor glucose metabolism with immune checkpoints in cancer treatment, and this innovative, safe, low-toxic, and highly effective anti-tumor strategy will have good clinical application prospects.
-
Infect? Super progressive? Elderly lung cancer patients have high fever after immunotherapy, and the "culprit" is ...
Time of Update: 2022-10-13
. ▌ Pseudo-progressive pseudo-progression (PP): refers to the initial increase in tumor size or new lesions after starting immunotherapy for a period of time, but this is not caused by the continued proliferation of tumors, the pseudo-progression rate of patients receiving ICIs treatment does not exceed 10%, common in non-small cell lung cancer and melanoma, the incidence in NSCLC is about 1.
-
Intraoperative MRI versus intraoperative ultrasound was used in the surgery of childhood brain tumors
Time of Update: 2022-10-13
, Department of Neurosurgery, University Hospital Bicoca, Milan, Italy, conducted a systematic literature review and meta-analysis to write about the differences between the cost and efficacy of intraoperative MRI and iOUS to assess tumor residuals, and the results were published in the August 2022 issue of the journal Childs Nerv Syst.
-
An article combs: EGFR/ALK TKI's past and present lives and the progress of third-generation drug research
Time of Update: 2022-10-13
The new generation of TKISeveral fourth-generation EGFR TKIs and ALK TKIs are currently under development with the goal of overcoming the "on-target" resistance of third-generation TKIs. EAI045 is an allosteric EGFR inhibitor, and preclinical studies have shown that EAI045 combined with cetuximab can successfully inhibit the growth of L858R-T790M mutation and T790M-T790M-C797S mutant lung cancer.
-
Express Milestones! Spot CAR-T therapies are entering critical clinical trials for the first time
Time of Update: 2022-10-13
▎Editor of WuXi AppTec content teamRecently, Allogene Therapeutics announced the commencement of its potentially critical Phase 2 clinical trial of the CAR-T therapy ALLO-501A, ALPHA2 。 According to the press release, this CAR-T therapy for the treatment of relapsed/refractory large B-cell lymphoma (LBCL) is the industry's first off-the-shelf CAR-T therapy to enter Phase 2 trials!
-
JCO: Does the Double Exemption Federation Improve the Recurrence-Free Survival of Advanced Melanoma?
Time of Update: 2022-10-13
(If you need the original text of the literature, you can add the small editor WeChat yxj_oncology to get) 1J Clin Oncol: Navurizumab combined with ipimumab does not improve recurrence-free survival in patients with stage IIIB-D or IV melanoma▎Clinical Problems: For high-risk resected melanoma, both navurizumab and ipimuzumab have shown therapeutic benefit.
-
Research Frontiers Efficacy and safety of radium-223 in patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases
Time of Update: 2022-10-13
Study the designEXCAAPE (NCT03002220) is a multicenter, single-armed, open-label, uncontrolled Phase IIa trial of 52 patients with mCRPC with asymptomatic BMS who developed progress after treatment with abiraterone or enzalumine.
-
i Hope time Professor Wang Yusheng's team: CAR-T therapy for the treatment of digestive tract tumors in China, the future can be expected!
Time of Update: 2022-10-13
At the same time, CAR-T (Chimeric antigen receptor T cell) therapy has also achieved remarkable success in the treatment of hematologic malignancies, and its application in solid tumors has also attracted much attention 。 On May 9, 2022, the team of Professor Shen Lin of Peking University Oncology Hospital published an article entitled "Claudin18.
-
Are you aware of the "hereditary tumor susceptibility syndrome" associated with an increased risk of stomach cancer?
Time of Update: 2022-10-13
According to the literature, germline truncation mutations of the tumor suppressor gene CDH1 (encoding the intercellular adhesion protein E-cadherin) have been found in 30% to 50% of HDGC patients' families.
-
2022CSH | Professor Wang Jin: CAR-T cell therapy is a double-edged sword, and the prospect of ALL new drug treatment is considerable
Time of Update: 2022-10-13
In recent years, he has published more than 30 academic works as the first or corresponding author in internationally renowned journalsAs the first person in charge, he undertook 8 projects, including major national science and technology cooperation projects, national natural science foundation projects and key projects of Shanghai Municipal Science and Technology Commission, and was selected as a "double hundred people" research physician in the Shanghai Municipal Education Commission's Summit Plateau Program - Jiaoyi Medicine.
-
Guidelines Overview China Guidelines for the Diagnosis and Treatment of Mantle Cell Lymphoma (2022 Edition)
Time of Update: 2022-10-13
Since the release of the "Chinese Expert Consensus on the Diagnosis and Treatment of Mantle Cell Lymphoma (2016 Edition)", it has greatly promoted the understanding of the disease among medical workers in China and standardized clinical diagnosis and treatment.
